APELOA(SZ:000739) Xin Lang Cai Jing·2025-11-20 08:25Core Viewpoint - Pro Pharmaceutical announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for Cefdinir capsules, which is classified as a Class 4 chemical drug, indicating a significant step in expanding its market presence and competitiveness in the pharmaceutical industry [1] Group 1: Drug Registration and Market Potential - The drug registration certificate is for Cefdinir capsules with a specification of 0.1g, which is expected to have a wide range of indications [1] - The estimated market size for the drug in China's hospital market for 2024 is projected to be 380 million capsules, with a sales value of 310 million yuan [1] - The total R&D investment for this drug has reached 5.2818 million yuan as of the announcement date [1] Group 2: Competitive Advantage and Market Factors - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation, which is expected to enhance sales and improve competitive positioning [1] - However, the production and sales of the drug may be influenced by various factors, including policies and market conditions [1]